Min Lu

Prof. Min Lu

University of Miami Miller School of Medicine, Miami, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 January 2018 in Journal of Computational and Graphical Statistics
Verified
Journal Article
Closed access
Min LuMin Lu
Min Lu
SSSaad Sadiq
Saad Sadiq
DFDaniel J. Feaster
Daniel J. Feaster
HIHemant Ishwaran
Hemant Ishwaran
Estimation of individual treatment effect in observational data is complicated due to the challenges of confounding and selection bias. A useful inferential framework to address this is the counterfactual (potential outcomes) model, which takes the hypothetical stance of asking what if an individual had received both treatments. Making use of random forests (RF) within the counterfactual framework we estimate individual treatment effects by directly modeling the response. We find that accurate estimation of individual treatment effects is possible even in complex heterogenous settings but that the type of RF approach plays an important role in accuracy. Methods designed to be adaptive to confounding, when used in parallel with out-of-sample estimation, do best. One method found to be especially promising is counterfactual synthetic forests. We illustrate this new methodology by applying it to a large comparative effectiveness trial, Project Aware, to explore the role drug use plays in sexual risk. The analysis reveals important connections between risky behavior, drug usage, and sexual risk. Supplementary material for this article is available online.

23 August 2022 in Annals of Surgery
Verified
Journal Article
Closed access
SRSiva Raja
Siva Raja
TRThomas W. Rice
Thomas W. Rice
Min LuMin Lu
Min Lu
MSMarie E. Semple
Marie E. Semple
EBEugene H. Blackstone
Eugene H. Blackstone
FIfor the Worldwide Esophageal Cancer Collaboration Investigators
for the Worldwide Esophageal Cancer Collaboration Investigators
Objective: We hypothesized that, on average, patients do not benefit from additional adjuvant therapy after neoadjuvant therapy for locally advanced esophageal cancer, although subsets of patients might. Therefore, we sought to identify profiles of patients predicted to receive the most survival benefit or greatest detriment from adding adjuvant therapy. Background: Although neoadjuvant therapy has become the treatment of choice for locally advanced esophageal cancer, the value of adding adjuvant therapy is unknown. Methods: From 1970 to 2014, 22,123 patients were treated for esophageal cancer at 33 centers on 6 continents (Worldwide Esophageal Cancer Collaboration), of whom 7731 with adenocarcinoma or squamous cell carcinoma received neoadjuvant therapy; 1348 received additional adjuvant therapy. Random forests for survival and virtual-twin analyses were performed for all-cause mortality. Results: Patients received a small survival benefit from adjuvant therapy (3.2±10 months over the subsequent 10 years for adenocarcinoma, 1.8±11 for squamous cell carcinoma). Consistent benefit occurred in ypT3–4 patients without nodal involvement and those with ypN2–3 disease. The small subset of patients receiving most benefit had high nodal burden, ypT4, and positive margins. Patients with ypT1–2N0 cancers had either no benefit or a detriment in survival. Conclusions: Adjuvant therapy after neoadjuvant therapy has value primarily for patients with more advanced esophageal cancer. Because the benefit is often small, patients considering adjuvant therapy should be counseled on benefits versus morbidity. In addition, given that the overall benefit was meaningful in a small number of patients, emerging modalities such as immunotherapy may hold more promise in the adjuvant setting.

11 March 2023 in Nursing Research
Verified
Journal Article
Closed access
RGRosa M. Gonzalez-Guarda
Rosa M. Gonzalez-Guarda
BMBrian E. McCabe
Brian E. McCabe
GNGabriela A Nagy
Gabriela A Nagy
ASAllison M. Stafford
Allison M. Stafford
LMLisvel Matos
Lisvel Matos
RCRichard C. Cervantes
Richard C. Cervantes
Background: The process of immigration and subsequent adaptation can expose Latinx immigrants to chronic and compounding challenges (i.e., acculturative stress), but little is known about how resilience factors and these stressors interact to influence syndemic conditions, intertwined epidemics that disproportionally affect historically marginalized communities. Objectives: The purpose of this study was to describe the influence of acculturative stress and resilience on the syndemic factor underlying substance abuse, intimate partner violence, HIV risk, and mental conditions. Methods: Baseline cross-sectional data from a community-engaged, longitudinal study of 391 adult (ages 18–44 years) Latinx immigrants in North Carolina were obtained using standardized measures available in English and Spanish. Structural equation modeling tested the syndemic model, and random forest variable importance identified the most influential types of acculturative stressors and resilience factors, including their interactions, on the syndemic factor. Results: Results indicated that a single syndemic factor explained variations in heavy drinking, drug use, intimate partner violence, depression, and anxiety and fit the data well. Age, being a woman, acculturative stress, acculturation to the United States, and emotional support were significantly related to the syndemic factor. The relationship between acculturative stress and the syndemic factor was buffered by ethnic pride, coping, enculturation, social support, and individual resilience. The most influential acculturative stressors were marital, family, and occupation/economic stress. Discussion: Findings from this study underscore the importance of considering the co-occurrence of behavioral and mental health conditions among Latinx immigrants. Health promotion programs for Latinx immigrants should address acculturative stress and bolster ethnic pride, social support, and coping as sources of resilience.

1 March 2018 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
Min LuMin Lu
Min Lu
HIHemant Ishwaran
Hemant Ishwaran

1 December 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TRThomas W. Rice
Thomas W. Rice
Min LuMin Lu
Min Lu
HIHemant Ishwaran
Hemant Ishwaran
EBEugene H. Blackstone
Eugene H. Blackstone